Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges

Pharming Group reported Q1 2026 revenue of EUR 72.4 million, down 8% year over year, as RUCONEST fell 15% amid inventory normalization and competition, partially offset by 34% growth in Joenja to $14.1 million. The company maintained full-year 2026 revenue guidance of $405 million-$425 million and positive operating cash flow of EUR 2 million, while outlining near-term catalysts from Joenja pediatric, Europe, and Japan launches. The stock was under pressure recently, but management emphasized patient retention, new prescriber growth, and expanding pipeline optionality.

Analysis

PHAR is in a transition phase where headline revenue volatility is less important than the mix shift in its value drivers. The core issue is that the legacy cash engine is no longer a pure growth asset, so investors are now pricing it like a fading franchise; meanwhile, the newer asset is still too small to fully offset near-term deceleration. That creates a setup where the stock can stay cheap longer than fundamentals would suggest unless the market starts to believe the new-product ramp is self-funding.

The key second-order effect is that competition is not just taking share; it is changing ordering behavior and forcing physicians to re-triage patients by severity. That can actually help the incumbent in the high-acuity niche because it increases the visibility of who truly needs rapid on-demand therapy, but it also means quarterly numbers will remain lumpy as reordering cycles normalize over the next 1-2 quarters. The market is likely underestimating how much of the near-term delta comes from timing rather than durable erosion.

The real catalyst stack is in the next 6-9 months: pediatric expansion, European launch, Japan launch, and two proof-of-concept readouts in adjacent immune-dysregulation populations. If even one of those expands the addressable market with credible reimbursement traction, the multiple should re-rate because the company stops looking like a single-asset story with a declining base. The contrarian view is that the current selloff may be overdone if investors are extrapolating the quarter instead of the launch cadence; the bear case only wins if the new launches slip while legacy share loss accelerates faster than expected.

Key Decisions for Investors

• Initiate a tactical long in PHAR for 3-6 months on weakness, sized small: the risk/reward improves if the market is over-discounting launch timing and underpricing the cash generation from the legacy franchise.
• Buy PHAR January 2027 calls or call spreads to capture the 6-9 month catalyst window; structure should benefit from a re-rating on pediatric Europe/Japan execution without requiring immediate top-line inflection.
• Pair trade: long PHAR / short a basket of large-cap healthcare names with slower growth and richer multiples; the idea is that PHAR’s catalyst density is higher over the next two quarters if execution holds.
• If holding PHAR outright, add only on confirmation of pediatric FDA acceptance and initial EU launch traction; those are the first signals that the growth engine is monetizing faster than the legacy decline.
• Avoid shorting into the current weakness unless you have conviction that patient reordering stabilizes lower than management guides; the downside is likely limited by cash flow support and multiple compression already in the stock.